Socrodeucitinib for psoriasis phase 2 trial

[Waine]

AI gives an explanation

Pharmaceutical names like socrodeucitinib might sound like mouthfuls, but they are built like linguistic Lego sets following strict rules established by the World Health Organization (WHO) through the International Nonproprietary Name (INN) system.

When regulators standardise a generic drug name, it is broken down into distinct functional parts:
The Anatomy of Socrodeucitinib
Prefix (Unique)socro-+Infix (Chemical Modification)-deu-+Stem (Drug Class/Mechanism)-citinib
1. The Stem: -citinib

    What it means: Standard stem for Janus kinase (JAK) inhibitors (including selective TYK2 inhibitors).

    Why it’s used: Whenever you see a drug name ending in -citinib (like tofacitinib, baricitinib, or deucravacitinib), it tells clinicians immediately that the drug blocks JAK family signaling pathways involved in immune and inflammatory responses.

2. The Infix: -deu- (or -deucitinib)

    What it means: Indicates deuteration.

    Why it’s used: Deuterium is a heavy, non-radioactive isotope of hydrogen. Replacing specific hydrogen atoms with deuterium in a molecule slows down its breakdown by liver enzymes, allowing the drug to last longer in the body or improve target selectivity. The -deu- sub-stem gained prominence with deucravacitinib (Sotyktu) and continues in newer deuterated allosteric TYK2 inhibitors like socrodeucitinib.

3. The Prefix: socro-

    What it means: A unique, arbitrary prefix selected by the drug's developers (Hansoh Biopharmaceutical).

    Why it’s used: The WHO INN committee requires every prefix to be distinct so no two medications sound or look too similar. This prevents dangerous mix-ups when doctors write prescriptions.

Summary

    socro- = Distinct identifier for this specific molecule.

    -deu- = Features deuterium atoms in its chemical structure.

    -citinib = Inhibits JAK/TYK2 enzymes to reduce inflammation.